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Abstract 
Background: Reactivation of Epstein-Barr virus (EBV) infection may cause serious, 
life-threatening complications in immunocompromised individuals. EBV DNA is often 
detected in EBV-associated disease states, with viral load believed to be a reflection 
of virus activity. Two separate real-time quantitative polymerase chain reaction 
(QPCR) assays using SYBR Green I dye and a single quantification standard 
containing two EBV genes, Epstein-Barr nuclear antigen-1 (EBNA-1) and BamHI 
fragment H rightward open reading frame-1 (BHRF-1), were developed to detect and 
measure absolute EBV DNA load in patients with various EBV-associated diseases. 
EBV DNA loads and viral capsid antigen (VCA) IgG antibody titres were also 
quantified on a population sample. 
 
Results: EBV DNA was measurable in ethylenediaminetetraacetic acid (EDTA) 
whole blood, peripheral blood mononuclear cells (PBMCs), plasma and 
cerebrospinal fluid (CSF) samples. EBV DNA loads were detectable from 8.0 x 102 
to 1.3 x 108 copies/ml in post-transplant lymphoproliferative disease (n = 5), 1.5 x 103 
to 2.0 x 105 copies/ml in infectious mononucleosis (n = 7), 7.5 x 104 to 1.1 x 105 
copies/ml in EBV-associated haemophagocytic syndrome (n = 1), 2.0 x 102 to 5.6 x 
103 copies/ml in HIV-infected patients (n = 12), and 2.0 x 102 to 9.1 x 104 copies/ml in 
the population sample (n = 218). EBNA-1 and BHRF-1 DNA were detected in 11.0% 
and 21.6% of the population sample respectively. There was a modest correlation 
between VCA IgG antibody titre and BHRF-1 DNA load (rho = 0.13, p = 0.05) but not 
EBNA-1 DNA load (rho = 0.11, p = 0.11).  
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Conclusion: Two sensitive and specific real-time PCR assays using SYBR Green I 
dye and a single quantification standard containing two EBV DNA target, were 
developed for the detection and measurement of EBV DNA load in a variety of 
clinical samples. These assays have application in the investigation of EBV-related 
illnesses in immunocompromised individuals.
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Background 
Epstein-Barr virus (EBV) causes infectious mononucleosis, an acute but self-limiting 
disease affecting children and young adults. After primary infection, the virus persists 
indefinitely in B-lymphocytes [1], only to reactivate when cellular immunity is 
impaired. In immunocompromised individuals, EBV-related disorders following virus 
reactivation are associated with significant morbidity and mortality [2]. Up to 15% of 
transplant recipients develop post-transplant lymphoproliferative disease (PTLD), a 
heterogeneous group of disorders characterised by EBV transformation of 
lymphocytes [3, 4]. Although uncommon, PTLD is aggressive and coupled with high 
mortality rates of 50-80% [4]. Also related to other diseases in immunosuppressed 
individuals, including chronic active EBV, fatal infectious mononucleosis (IM) and 
EBV-associated haemophagocytic syndrome (EBVAHS) [5-7], EBV is linked to 
several malignancies such as nasopharyngeal carcinoma (NPC) and Burkitt's 
lymphoma (BL) [5]. In HIV-infected individuals, EBV is associated with diseases such 
as oral hairy leukoplakia and AIDS-related non-Hodgkin’s lymphoma [5, 8].  
 
Though sometimes detectable in the immunocompetent [9], EBV DNA is found in 
greater concentrations in immunosuppressed populations [10-13]. The presence of 
circulating EBV DNA does not always correlate with symptomatic infection, nor does 
it predict clinical disease in immunocompetent or immunosuppressed individuals [2, 
9]. Nevertheless, although the correlation between EBV burden and disease status is 
incompletely understood, several studies have shown an association between 
symptomatic infection and elevated DNA loads in clinical samples [14, 15]. 
Increasing virus burden is also believed to be a rapid indicator of 
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immunopathological changes preceding and/or underlying the B-lymphocyte driven 
changes caused by EBV [16]. Therefore, determining EBV DNA loads in EBV-related 
disorders in immunocompromised populations is an important step towards disease 
diagnosis, management and treatment [17].  
 
Several methods for quantifying absolute DNA load have been developed since its 
first application to EBV diagnostics in 1999 [18-20]. These include semi-quantitative, 
quantitative competitive and real-time PCR methods [21], with each using different 
means for amplicon detection; visualisation on agarose gel, Southern blot analysis 
and enzyme immunoassay [21]. Real-time PCR quantification is generally preferred 
for its wider dynamic range, speed, ease of handling, sensitivity and specificity [2, 
22-25]. Although commercial assays incorporating probe-based chemistries are 
available [26, 27], in-house methods employing high saturating dyes such as SYBR 
Green I are more cost-effective and just as sensitive as the widely used TaqMan 
PCR [21, 28-30].  
 
Here, in an effort to ascertain the relationship between EBV DNA load and disease, 
two real-time quantitative PCR (QPCR) assays using SYBR Green I dye and a single 
quantification standard incorporating two separate EBV genes, Epstein-Barr nuclear 
antigen-1 (EBNA-1) and BamHI fragment H rightward open reading frame-1 (BHRF-
1), were developed. EBV DNA was measured in a range of clinical samples, 
including unfractionated whole blood, plasma, PBMC and CSF from patients with 
EBV-associated disorders or immune dysfunctions. EBV sero-status was also 
  6 
determined for individuals in a population sample to assess the correlation between 
DNA load and antibody titres. 
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Methods 
Groups with EBV-associated diseases or immune disorders 
A total of 60 clinical samples from 25 individuals with various EBV-associated 
diseases or immune disorders were collected between February 2007 and 
September 2008. Specimen types included EDTA whole blood, plasma, PBMC and 
CSF. Each patient was assigned a letter (A to Y) and classified into one of four 
groups. Group 1 consisted of five patients with EBV-related PTLD following 
matched-unrelated donor haematopoietic stem cell transplantation, generating 40 
samples: whole blood (n = 20), plasma (n = 18) and CSF (n = 2). Group 2 consisted 
of seven patients with IM, with plasma (n = 4) or whole blood (n = 3) samples and 
Group 3 was based on a single patient with EBVAHS from whom a whole blood 
sample was available. Group 4 consisted of PBMC (n = 3) and plasma (n = 9) 
samples from 12 HIV-infected individuals with HIV RNA plasma loads greater than 
10,000 copies/ml. 
 
Population sample 
A fifth group was comprised of 218 individuals from a population sample for whom 
whole blood and serum were collected between 2004 and 2007. This included 46 
males and 172 females with a mean age of 39 (SD = 10) and 40 (SD = 9.5) years 
respectively. These individuals resided in one of four regions in eastern Australia 
including Brisbane (n = 78), Newcastle (n = 28), Geelong and the western districts of 
Victoria (n = 45) and Tasmania (n = 67) [31]. 
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Serology testing 
EBV-specific antibody detection in the population sample 
Quantitative EBV-specific serology was performed on sera from individuals in Group 
5 only. EBV VCA IgG antibodies titres were determined by an immunofluorescence 
assay (IFA) using FITC conjugated anti-human IgG prepared in goats (Sigma-
Aldrich, Castle Hill, NSW, Australia). Cells from the B95-8 marmoset cell line 
productively infected with EBV were grown in 27 mls of RPMI 1640-modified 
(ThermoFisher Scientific, Scoresby, VIC, Australia) +10% foetal calf serum (FCS) 
(ThermoFisher Scientific, Scoresby, VIC, Australia) medium containing 3 mls of 0.4 
mM phosphonoacetic acid (Sigma-Aldrich, Castle Hill, NSW, Australia). Cells were 
spotted on 10 well slides (Pathech, Preston, VIC, Australia) and used as the antigen. 
Four-fold dilutions of known EBV positive sera were used as controls. Samples were 
diluted using phosphate buffered saline containing 10% FCS four-fold from 1:10 to 
an endpoint; samples with a titre < 1:10 were reported as negative, whilst titres equal 
to or greater than 1:10 were defined as positive.  
 
Molecular testing 
EBV gene targets, beta-globin and PCR controls 
To maximise detection rates and reduce false negative results, two primer sets 
targeting the highly conserved EBV regions, EBNA-1 and BHRF-1, were used for 
PCR amplification (Table 1). EBNA-1 is a latent protein required for replication and 
genome maintenance and is the only viral protein consistently expressed in EBV-
infected cells [32, 33]. BHRF-1 is expressed in lytic infection and confers anti-
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apoptotic properties similar to Bcl-2 for enhancing cell survival [34]. Groups 2-5 were 
evaluated by both PCR targets, while inadequate sample volume limited testing to 
EBNA-1 in Group 1. The beta-globin gene targeting the TAL57 region was used as a 
‘house-keeping’ gene to control for PCR inhibitors and check for DNA integrity [35]. 
All samples were subjected to beta-globin PCR prior to EBV QPCR. Contamination 
was monitored by the use of PCR-grade water and no template DNA controls. 
 
DNA extraction and molecular assay design  
DNA was isolated from 200 µl of EDTA whole blood, plasma or CSF using the 
GenElute™ Mammalian Genomic DNA Miniprep Kit® (Sigma-Aldrich, Caste Hill, NSW 
Australia) according to the manufacturer’s instructions, and eluted in 200 µl elution 
buffer. The QIAamp DNA mini kit (Qiagen, Doncaster, VIC, Australia) was used to 
extract DNA from PBMC in accordance with the manufacturer’s instructions. Extracts 
were aliquoted in single use volumes to prevent freeze-thaw cycles and stored at -
80°C prior to testing. Each reaction mixture was contained in a PCR-certified 
colourless 200 µl flat capped tube (Integrated Sciences, Willoughby, NSW, Australia) 
to a final 25 µl volume, comprising of 2.0 µl LightCycler® FastStart DNA Master 
SYBR Green 1 dye (Roche Diagnostics, Castle Hill, NSW, Australia) at 10X 
concentration pre-combined with the LightCycler® FastStart enzyme, 0.5 µl of 0.2 
mM sense and antisense primers (Invitrogen, Mount Waverley, VIC, Australia), 0.8 µl 
25 mM MgCl2 and 5 µl of the DNA eluate. Samples were tested on the 36-well rotor 
on the Rotor-Gene 6000® analyser (Qiagen, Doncaster, VIC, Australia). PCR was 
divided into two cycles: a first cycle with three repeats at 40 seconds for each stage, 
and a second cycle with 40 repeats at 30 seconds per stage. Thermal cycling 
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conditions included an optimised initial denaturation step followed by 95°C 
denaturation, optimised annealing temperatures and extension at 72°C (Table 1). To 
ensure complete product formation, a final extension step at 72°C for 5 minutes 
concluded the PCR. A melt analysis immediately followed at between 60°C to 99°C 
as a check for amplicon purity. For confirmation, EBNA-1 and BHRF-1 products were 
electrophoresed in 2% agarose gel containing 1:20 dilution of SYBR® safe DNA gel 
stain in 0.5X TBE buffer (Invitrogen, Mount Waverley, VIC, Australia). 
 
Cloning of EBNA-1 and BHRF-1 DNA targets into plasmid vector pGEM and 
standard curve construction 
A novel feature of the assay was the design of a quantification standard 
incorporating both EBNA-1 and BHRF-1 DNA targets in a single plasmid (Figure 1). 
This was done to minimise the necessity for two separate EBV standards, thus 
reducing costs and labour. The EBNA-1 and BHRF-1 DNA targets were linked using 
randomised primers (Table 1) and inserted into the pGEM vector, using the pGEM®-
T Easy Vector System II (Promega Corporation, Alexandria, NSW, Australia) 
according to the manufacturer’s instructions. The cloned targets were then purified 
using the PureYieldTM Plasmid MidiPrep System (Promega Corporation, Alexandria, 
NSW, Australia), and stored in single use aliquots. Target copy number was 
calculated following double stranded DNA approximation using the Beckman DU® 
530 Life Science UV/Vis spectrophotometer (Beckman Coulter, Gladesville, NSW, 
Australia). A new plasmid aliquot was used for standard curve dilution for each PCR 
run consisting of three replicates starting at 101 to 106 copies/5µl. PCR runs were 
accepted when the standard curve correlation co-efficient was ≥ 0.99. 
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Product identification, reproducibility, sensitivity, limit of detection and 
specificity  
PCR products were identified by an amplification curve, melt analyses and 
amplification efficiency generated by the Rotor-GeneTM 6000 Software 1.7 (Build 90). 
Positive EBV DNA samples had a cycle threshold (CT) less than 40, and melted 
between 86°C to 87°C with an average amplification efficiency of 1.74. PCR 
products for EBNA-1 DNA and BHRF-1 DNA were identified on agarose gel by 213 
bp and 208 bp bands, respectively. Reproducibility studies consisting of triplicates of 
each standard curve dilution (101-105 copies/5µl) were performed prior to testing. 
Intra-assay variation was determined in three repeat assays tested within 24 hours 
on three consecutive days. Inter-assay variation was assessed using three different 
batches of the same PCR master mix kit. Sensitivity was determined by end-point 
PCR using gel electrophoresis. To establish the minimum DNA copy number that 
could be reliably detected, ten plasmid replicates spanning 100 to 102 copies/5µl 
were assayed in three separate runs. Primer specificity was verified on the Basic 
Local Alignment Search Tool on GenBank and by assaying known cytomegalovirus 
(CMV), human herpesvirus 6 (HHV6), HIV and varicella zoster (VZV) positive 
samples. The EBV QPCR was evaluated against an external quality assurance 
program (Quality Control for Medical Diagnostics (QCMD), Glasgow, Scotland, 
[http://www.qcmd.org/]) for EBV QPCR in 2008 and 2009. 
 
Viral load calculation and result interpretation 
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Viral load calculations were based on DNA extraction volume and final elution 
volumes as well as the number of replicates tested. Samples were extracted and 
eluted in equal quantities, keeping ratios constant. Hence, the amount of sample 
used for PCR (5 µl) was multiplied by a factor of 200 (elution volume) and divided by 
the number of replicates to obtain a final measurement expressed as DNA copies 
per millilitre (copies/ml) of sample. This unit of measurement has close correlations 
with copies per microgram of DNA, therefore does not require normalisation to the 
amount of input DNA [36]. Furthermore, copies/ml removes unnecessary processing 
steps and reduces costs, as well as minimising sample volume for testing. EBV DNA 
was quantifiable in a dynamic range spanning six logarithms with the minimum 
reportable viral load at 2.0 x 102 copies/ml of sample. Samples with no detectable 
target DNA were assigned a load of zero and resulted as negative.  
 
Statistical calculations 
Data analysis was conducted with SPSS version 17. Spearman’s (rho) correlation 
co-efficient was used to assess the correlations between EBNA-1 and BHRF-1 DNA 
loads and VCA IgG antibody titres. 
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Results  
Performance of EBV QPCR assays: reproducibility, sensitivity, detection limit 
and specificity 
The intra-assay and inter-assay co-efficient of variation for EBNA-1 and BHRF-1 
QPCRs are shown in Table 2. Both EBV targets were detected at levels as low as 
2.0 x 102 copies/ml of sample. However, the reliable limit of detection for both EBNA-
1 and BHRF-1 DNA was 2.0 x 103 copies/ml, where the proportion that were 
detected (positivity ratio) were 97% and 93% respectively. Primers showed no cross 
reactivity to other herpesviruses (data not shown). All samples in both the 2008 and 
2009 QCMD programs were correctly identified using the EBNA-1 primers. 
 
EBV detection and load in EBV-associated disease states and 
immunocompromised individuals 
Of the 60 samples from 25 immunocompromised patients, 30 (50%) samples from 
16 (64%) patients had quantifiable viral load using one or other of the EBV DNA 
targets, EBNA-1 or BHRF-1 (Table 3). EBV DNA was detected in 100%, 85.7%, 
100% and 33.3% of patients with PTLD, IM, EBVAHS and HIV-infected individuals 
(Groups 1 to 4), respectively. EBV DNA loads were detectable at ranges from 2.0 x 
102 to 1.3 x 108 copies/ml in these clinical samples, with the highest EBV DNA load 
recorded in an individual with PTLD (1.3 x 108 copies/ml of sample). High levels 
were also seen in individuals with IM (2.0 x 105 copies/ml of sample), EBVAHS (1.1 x 
105 copies/ml whole blood), and HIV infection (5.6 x 103 copies/ml of sample).  
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In Group 1 (PTLD), EBV DNA concentrations spanned six logarithms and were 
detected in multiple samples from early to end-stage disease. EBV DNA loads 
increased sequentially following transplantation, decreased after anti-viral therapy in 
Patients A and C and peaked ten days prior to death in Patients A to D. EBV DNA 
loads were detectable in some samples, but were absent in others. In Patient D, 
plasma EBV DNA was qualitative PCR negative on Day +62 whilst simultaneously 
QPCR positive in whole blood. EBV-specific serology results were available for four 
patients, and confirmed EBV infection prior to the transplant. Four patients died as a 
result of PTLD complications, on average +81.25 days post transplantation. In Group 
2 (IM), EBV DNA was quantifiable from 1.5 x 103 to 2.0 x 105 copies/ml. One sample 
was negative for EBV DNA (Patient G), despite a positive EBV VCA IgM profile. 
Group 3 (EBVAHS) EBV DNA load results were similar to Group 2, however Patient 
M died as a consequence of the disease condition. In Group 4 (HIV), EBV DNA was 
detectable in both plasma and PBMC ranging from 2.0 x 102 to 5.6 x 103 copies/ml. 
However, 50% of these samples were below 2.0 x 103 copies/ml. 
 
EBV detection and load in the population sample 
EBNA-1 and BHRF-1 DNA were detected in 11.0% and 21.6% of Group 5 (the 
population sample), respectively; 22.5% of samples were positive for at least one 
EBV DNA target (Table 4). Of the 24 EBNA-1 DNA positive samples, 91.7% were 
also BHRF-1 DNA positive, and of the 47 BHRF-1 DNA positive samples, 46.8% 
were also EBNA-1 DNA positive. Viral loads (combined targets) were detectable 
between 2.0 x 102 to 6.2 x 104 copies/ml of whole blood, but 54.2% and 85.1% of 
samples were below 2.0 x 103 copies/ml for EBNA-1 and BHRF-1 DNA levels, 
respectively. All samples with measurable EBV DNA were EBV VCA IgG antibody 
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positive, which were found in 95.9% of the population sample. There was a modest 
correlation between VCA IgG antibody titres and BHRF-1 DNA load (Spearman’s rho 
= 0.13, p = 0.05) and a weaker (not statistically significant) correlation between 
EBNA-1 DNA load and VCA IgG antibody titres (Spearman’s rho = 0.11, p = 0.11) 
(Table 4). 
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Discussion 
With increasing availability of nucleic acid testing (NAT) methods, measuring EBV 
DNA in blood has proven valuable in diagnosing and monitoring PTLD [16, 21, 22, 
37-41], NPC [42, 43], IM [13, 44], EBV infection in HIV-infected individuals [8, 13, 
45], BL [13] and chronic active EBV infection [18, 46]. In this study, we successfully 
developed two in-house QPCR methods incorporating a novel single quantification 
standard containing two EBV DNA targets for measuring viral load on the Rotor-
Gene 6000™. Substituting SYBR Green I dye as a fluorescent marker for product 
accumulation over fluorogenic probes, this method proved useful for quantifying EBV 
DNA concentrations in clinical samples from individuals with a variety of EBV-
associated disorders or immune dysfunctions and in a healthy population sample.  
 
Previous studies in PTLD have found that EBV DNA loads increased with disease 
progression and decreased with remission of lymphoproliferation [47, 48]. This 
pattern was observed in Group 1, where EBV DNA loads appeared to be correlated 
with disease status. We found similar EBV DNA loads to those previously reported, 
with most studies showing EBV DNA concentrations ranging from 5.0 x 102 to 2.0 x 
107 copies/ml in whole blood, plasma and serum [37, 49, 50]. EBV DNA was also 
detected in CSF at concentrations comparable to plasma, however detectable CSF 
EBV DNA has been previously reported only in association with acquired 
immunodeficiency syndrome (AIDS)-related brain lymphoma [51]. The significance of 
EBV DNA in CSF of PTLD remains to be elucidated.  
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EBV DNA loads in IM patients were also similar to those reported in the literature 
[13, 22, 26, 44, 52], although some authors described loads as high as 106 and 107 
copies/ml [12, 46, 53]. In Group 3, EBV DNA loads were consistent with acute phase 
EBVAHS [46, 54], and correlated with the deterioration of the patient’s disease 
condition. Elazary et al also found that a viral load ranging from 104-105 copies/ml 
was associated with poor patient outcome [54]. One study found much higher EBV 
DNA loads (up to 107 copies/ml) [55], but this may have been due to differences in 
sample type and detection methods. In Group 4, EBV DNA was detected in 33% of 
samples (22% of plasma, 67% of PBMC), compared to 34% to 76% positivity 
reported in other studies [8, 26]. Notably however, these studies used whole blood 
for quantifying EBV DNA load, which could have increased the probability of viral 
DNA detection. As none of the Group 4 patients were known to have EBV-related 
disease, low positivity ratios and viral loads were expected.  
 
Similar to our findings, the literature describes EBV DNA detectable from 102 to 104 
copies/ml and positivity ratios up to 29% in whole blood of healthy individuals [11-13, 
26, 38, 56-59]. However, DNA loads as high as 5.5 x 105 copies/ml of whole blood 
and a positivity ratio of 72% have been reported [58]. Differences in the results may 
be attributable to more sensitive methods associated with nested PCR and dual-
labelled probes [58]. Interestingly, another study showed 100% EBV DNA positivity 
in whole blood, although DNA loads were all below the detection limit of the assay 
(2.0 x 103 copies/ml) [38].  
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In the population sample the EBV VCA IgG antibody detection rate was consistent 
with levels of EBV sero-positivity in Western societies [2]. One study previously 
showed a correlation between EBV VCA IgG antibody titres and EBV viral load 
(detectable versus non-detectable) [60]. We similarly found a modest correlation with 
quantitative BHRF-1 DNA loads, and a weaker (not statistically significant) 
correlation with EBNA-1 DNA load (see Table 4). 
  
We noted some discrepancies in our measures of EBV positivity. In one PTLD 
patient (Patient D), plasma was qualitative EBV PCR negative whilst simultaneously 
reporting an EBV DNA load of 1.3 x 108 copies/ml in whole blood. However, a 
growing number of studies have shown that cell-associated EBV is detectable before 
plasma EBV DNA and can persist without accompanying plasma DNA loads [21, 48]. 
In Group 2, Patient G, despite being EBV VCA IgM antibody positive, was EBV 
QPCR negative. As EBV DNA loads can change rapidly from being undetectable to 
being very high in a short period of time [38], it is possible that sampling occurred 
late in the convalescent phase where low EBV DNA positivity ratios of 44% have 
been previously reported [46]. Other factors contributing to DNA load variation 
include differences in sample type, method of extraction or NAT, and target chosen 
for PCR amplification.  
 
As specimen type is known to influence DNA loads and impact on assay 
performance [36], unfractionated EDTA whole blood was used for DNA quantification 
where possible. The dynamic changes of EBV DNA are better reflected in circulating 
whole blood [38], which also contains all the compartments that may harbour virus 
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[13, 21, 61]. However, despite reports of greater test sensitivity with whole blood [12, 
36], EBV DNA load has also been quantified in PBMC [14, 16, 62-64]. Although 
infection is typically associated with cell compartments [8, 12, 13], EBV DNA is also 
found in cell-free blood partitions such as plasma or serum, usually in fragmented, 
cell-derived form [12]. In this study, 2 of 9 plasma samples from HIV-infected 
patients had detectable EBV DNA, compared to 2 out of 3 PBMC samples. As we 
did not have simultaneous plasma and PBMC samples from the same individuals, 
we were unable to assess the differences in viral load between these compartments. 
Further studies comparing suitability of different sample types in various EBV-related 
diseases and immune disorders are required. 
 
The method of DNA purification is known to affect viral load measurements. One 
study showed yield from manually extracted DNA was 57% higher than that of 
robotic systems [65]. Therefore, to improve DNA recovery and maximise PCR 
sensitivity, samples here were purified using a commercial silica-based column 
method [61, 66]. For optimal quantitation results, an earlier study showed that DNA 
should be subjected to PCR within one to two weeks post-extraction [67]. Here, 
delay between extraction and testing could have contributed to low DNA loads and 
positivity ratios in clinical samples. Furthermore, DNA from blood samples that had 
undergone more than four freeze-thaw cycles were found to be partially degraded 
[68]. Since the clinical samples used here were tested retrospectively, monitoring 
these conditions were not possible.  
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EBV DNA loads also vary according to type and size of gene target [69]. Ryan et al, 
found assay sensitivity was dependent on the specific gene segment and that 
different targets had varying lower limits of detection [15]. For EBV, BamHI-W is 
reportedly 10 times more sensitive than other targets for PCR, allowing for detection 
of viral DNA at trace amounts [8, 13, 15]. However, precise quantification of viral 
genomes is complicated by the number of reiterated BamHI-W sequences among 
EBV strains, which typically ranges between 7 and 11 repeats per genome [15]. To 
avoid overestimation in this study, we chose to use the next most sensitive EBV 
gene; EBNA-1 [15], and an abundantly expressed gene, BHRF-1, for QPCR.  
 
Despite targeting highly conserved EBV regions, selective drop out of amplifiable 
EBV DNA at the EBNA-1 and BHRF-1 loci was observed in Group 4 (Patients N and 
X), and in 25 of 218 (11.5%) whole bloods from the population sample. Instead of 
amplifying both EBV DNA genes, only one target was detected, 93% of which had 
viral loads less than 2.0 x 103 copies/ml. As beta-globin was detected in all samples, 
PCR inhibitors and/or defective nucleic acid purification methods were excluded [70]. 
Alternatively, selective drop out may have been due to low viral load and/or sampling 
error [71]. Since load determination is reliant on the amount of EBV genomes 
pipetted into a reaction and assumes viral homogeneity, QPCR results, particularly 
at low viral load levels are prone to random sampling error. This phenomenon is well 
documented in DNA quantification and results in less reliable viral load 
measurements [70, 71]. Therefore, samples reporting low levels of target nucleic 
acid may not be reproducible in repeated assays from the same or different 
specimens [72].  
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Currently, there are no standardised methods for measuring EBV DNA, complicating 
inter-laboratory comparisons in multicentre studies of EBV-related diseases. 
Standardisation is difficult as PCR assay conditions vary between laboratories, 
leading to variations in the accuracy and reproducibility of viral load quantification 
[21]. Although there appears to be a strong concordance between laboratories for 
qualitative EBV DNA estimates, there continues to be marked inconsistency in 
quantitative results [73]. It has been suggested that the use of unfractionated whole 
blood [26] or an international calibration standard could be the first step towards 
standardisation [73]. However, instrumentation, chemistries, gene targets and other 
test-related aspects remain diverse. One solution for enabling inter-laboratory 
comparisons is the distribution of proficiency panels such as QCMD. Such programs 
have already been used for assessing methods for the detection and quantification 
of EBV and other viruses [27, 74, 75]. 
 
Conclusion 
This is the first reported study that uses the SYBR Green I dye on the Rotor-gene 
6000TM with a novel quantification standard containing two EBV targets for 
measuring EBV DNA load. The assays proved successful in the quantification of 
EBV genomes in clinical cases and should be considered as a cost effective and 
sensitive PCR alternative to probe-based assays. This approach can be modified to 
detect and quantify other latent herpesviruses such as HHV6, CMV, and VZV. This 
procedure is suitable for robotics and automation, and would be a useful addition in 
larger laboratories. 
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Figure legend 
Figure 1 - Plasmid vector pGEM showing location of cloned insert.  
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